Anthem Biosciences Ltd

- No specific mention of any current or planned fundraising through debt or equity was made in the document. - Company is focusing on large capex investments, particularly Unit 4 expansion, funded through internal cash flows as indicated by mention of flexible cash situation. - Ajay Bhardwaj and Gawir Baig highlighted confidence in existing cash position enabling flexibility for potential acquisitions but no definite plans announced. - Emphasis is on organic growth and selective inorganic acquisition only if the right opportunity arises; no immediate fundraising tied to these. - Overall, no explicit indication of upcoming equity or debt fundraising in the near term.

- Major ongoing capex is for Unit 4, Anthem's largest project, spanning 30 acres. - Phase 1 investment of approx. Rs. 1,200 crores over FY27 and FY28, aiming for completion by March 2028. - Phase 1 will nearly double custom synthesis capacity (adding 365 kiloliters) and increase fermentation capacity by 50% (adding 100 kiloliters). - Unit 2 and Unit 3 expansions are ongoing (currently in CWIP). - Post Phase 1, two more phases planned for Unit 4 to further double or triple overall capacity. - FY27 capex expected around Rs. 700 crores; subsequent year around Rs. 500 crores. - Focus is on becoming future-ready with increased agility, technology investments, including automation, continuous processing, and green chemistry. - Open to inorganic growth through acquisitions but only when the right strategic fit is identified.

- Anthem Biosciences aims to maintain a revenue growth rate of around 20%, consistent with its historical performance over the past decade. - The company aspires to continue delivering around 20% growth in EBITDA and PAT alongside revenue growth. - Recent revenue growth was about 15% due to market adjustments, but EBITDA and PAT grew over 30%. - The launch of four new commercial molecules contributes around 8-9% to current revenues, with ramp-up expected over 2-3 years. - Capacity expansions, especially Unit 4 (doubling custom synthesis and increasing fermentation capacity by 50%), position the company for future growth. - The company anticipates broadening relationships with big pharma, expecting growth through new programs and acquisitions of biotech firms. - Specialty ingredients segment targets ~20% growth. - Restocking after destocking should positively impact top-line growth going forward.

- Anthem Biosciences aims to maintain historical revenue growth of around 20% annually over the medium to long term. - EBITDA margins are expected to remain stable around 38-40%, leveraging operating leverage and backward integration gains. - PAT growth has been strong (31% YoY in FY26), with aspirations to sustain similar trajectories supported by margin stability. - The ramp-up of recently commercialized molecules is expected to take 2-3 years, contributing around 8-9% of current revenues, signaling future earnings growth. - Major capex investments (Rs. 700 crores in FY27 and Rs. 500 crores thereafter) in Unit 4 expansion aim to substantially increase capacity and support growth. - Inorganic growth through acquisitions is being explored but will be undertaken only if quality and strategic fit are met. - The company expects further growth from increasing biotech funding, new client additions (including big pharma), and technology-driven service enhancements. - No specific forward-looking EPS guidance was provided, but overall outlook is positive with a focus on sustaining growth and profitability.

- Specialty Ingredients segment operates as a flow business without a traditional order book; products are manufactured and sold continuously to multiple customers across regions. - For the CDMO business, order books exist primarily with commercial molecule customers who provide significant lead times, typically up to six months. - No specific numeric details on overall pending orders or order book size are provided. - The company has around 100 projects in early stages (discovery, development, optimization), with capacity to handle up to 200 projects without constraints. - Expansion via Unit 3 and upcoming Unit 4 will increase capacity, supporting future order inflow. - No near-term guidance on total order book was shared, but management emphasized strong demand and customer trust. - Specialty Ingredients order momentum recovered with 8% growth in the latest quarter, and further growth expected with dedicated facilities planned.